Rome, Nov 5. (Adnkronos Health) – “The particular data on HPV vaccination coverage is that at least one dose administered in adolescence reaches 85% in Lombardy and Umbria, which are the two regions with the highest percentages, while coverage in some southern regions, particularly Sicily, is half” of this percentage. “We need to work to increase vaccination coverage, especially in those regions that are struggling more today. It’s a cultural factor, it’s an organizational factor, and it’s an approach that requires the collaboration of doctors and gynecologists. I believe there is still a lot of work to be done.” This was stated by Carlo Signorelli, Professor of Hygiene at Vita-Salute San Raffaele University in Milan, speaking at the conference ‘Elimination of HPV-related pathologies: utopia or real possibility?’, which brought together experts, scientific societies, institutions, and patient associations in Rome today.
“The vaccine against the papillomavirus was the first vaccine designed to prevent cancer, specifically cervical cancer – explains Signorelli -. Exactly twenty years ago, the first registration occurred, then another vaccine arrived shortly after. The cost was very high, so an amendment to the 2007 financial law was needed to allow twelve-year-old girls to receive the vaccine offered from the following year. It was an operation that gained broad political consensus. Initially, things went very well, then there was a decline in vaccination adherence and, in recent years, a recovery. In the meantime, however, we have a more effective vaccine available, the so-called nonavalent vaccine, which is now administered in all Italian regions and protects against nine serotypes dangerous for the development of cancerous pathologies.”
“It has been discovered that this virus, for which one gets vaccinated, is the cause not only of cervical cancer but also of six other types of cancer affecting both women and men – highlights the expert -. For this reason, since 2017, vaccination has begun to be offered not only to twelve-year-old girls but also to twelve-year-old boys. And that is what is being done today.” Twenty years after the introduction of the HPV vaccine, “we still do not have data indicating a clear decline in pathologies that develop during life. Surely, however, there is a great propensity to prevent cancer, as it represents an investment in the health of young people.” And precisely to safeguard the health of young people, “the National Health Service is currently recovering those who were not vaccinated at twelve years old and who can now do so up to thirty years old, in order to have lifelong protection from these six cancers,” he concludes.